UK markets close in 2 hours 29 minutes

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
45.04-0.53 (-1.16%)
As of 2:46PM CEST. Market open.
Full screen
Previous close45.57
Open45.18
Bid45.04 x N/A
Ask45.04 x N/A
Day's range44.89 - 45.36
52-week range31.03 - 46.53
Volume703,539
Avg. volume1,532,961
Market cap29.854B
Beta (5Y monthly)1.26
PE ratio (TTM)14.92
EPS (TTM)3.02
Earnings date30 Jul 2021
Forward dividend & yield0.88 (1.93%)
Ex-dividend date25 May 2021
1y target estN/A
  • Is FRESENIUS SE&CO (FSNUY) Stock Undervalued Right Now?
    Zacks

    Is FRESENIUS SE&CO (FSNUY) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Is FRESENIUS SE&CO (FSNUY) a Great Value Stock Right Now?
    Zacks

    Is FRESENIUS SE&CO (FSNUY) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • EQS Group

    Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21

    Fresenius SE & Co. KGaA / Key word(s): ForecastFresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/2101-Feb-2021 / 22:49 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21Current Group expectations for FY/21Based on the current status of the Group's financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth1 and at least broadly stable net income2 year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care's results and hence on Fresenius Group's net income2 growth.Group medium-term targetsThe current information and assumptions do not trigger a revision of Fresenius' medium-term growth targets, which were set before the COVID-19 pandemic emerged.Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.1 in constant currency2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programsFor additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.Fresenius SE & Co. KGaA,represented by Fresenius Management SE,The Management BoardBad Homburg v.d.H., February 1, 2021----------------------------------------Contact:Markus GeorgiSenior Vice President Investor Relations & SustainabilityT: +49 (0) 6172 608-2485markus.georgi@fresenius.com----------------------------------------End of Note01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: ir-fre@fresenius.com Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange EQS News ID: 1164992 End of Announcement DGAP News Service